Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. Co. is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. Co. is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. We show 51 historical shares outstanding datapoints in our coverage of SUPN's shares outstanding history.
Understanding the changing numbers of SUPN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SUPN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SUPN by allowing them to research SUPN shares outstanding history
as well as any other stock in our coverage universe. |
Free SUPN Email Alerts:
Video: Shares Outstanding Importance
